{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-279715","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.799482+00:00","generated_at":"2026-05-29T02:53:55.056491+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Trevi prices $50M underwritten offering of 12.5M shares at $4.00 per share","bullets":["Offering of 12.5M shares at $4.00/share; net proceeds ~$46.7M after underwriting discounts and expenses.","Participants include Adage Capital, Frazier Life Sciences, Logos Capital, MPM BioImpact, Rubric Capital, Vivo Capital.","Expected to close on December 17, 2024, subject to customary conditions.","Company developing Haduvio for chronic cough in IPF and refractory chronic cough.","Leerink Partners, Stifel, and Oppenheimer are joint book-running managers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-279715","json":"https://secwatch.observer/filing/0001193125-24-279715.json","markdown":"https://secwatch.observer/filing/0001193125-24-279715.md","text":"https://secwatch.observer/filing/0001193125-24-279715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000119312524279715/0001193125-24-279715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000119312524279715/d738809d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:53:55.056491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}